Ashraf Moeini Corresponding Author
1- Department of Gyn. & Obs., Medical Sciences/ Tehran University, Roointan-Arash Hospital, Tehran, Iran
2- Royan Research Center, Endocrinology & Infertility Department, Tehran, Iran
Mitra Mansoori
- Department of Gyn. & Obs., Medical Sciences/ Tehran University, Roointan-Arash Hospital, Tehran, Iran
Bita Eslami
- Department of Gyn. & Obs., Medical Sciences/ Tehran University, Roointan-Arash Hospital, Tehran, Iran
Afsaneh Tehranian
- Department of Gyn. & Obs., Medical Sciences/ Tehran University, Roointan-Arash Hospital, Tehran, Iran
Akram Seifollahi
- Department of Gyn. & Obs., Medical Sciences/ Tehran University, Roointan-Arash Hospital, Tehran, Iran

Received: 1/1/2008 Accepted: 1/1/2008 - Publisher : Avicenna Research Institute

Related Articles


Other Format



Introduction: Polycystic ovary syndrome (PCOS) is the most common cause of oligoovulation and anovulation in infertile women. Prolonged endometrial exposure to estrogen and unopposed by the inhibitory effects of progesterone in these patients makes them susceptible to endometrial hyperplasia. The objectives of this study, was to determine the prevalence of hyperplasia in PCOS patients and effect of factors such as age, body mass index and endometrial thickness on the abnormality. Materials & Methods: This cross-sectional study was conducted in Roointan-Arash Hospital during 2006 and out of 135 infertile women with PCOS, 106 patients were included in the analysis after considering the exclusion criteria. Patients were admitted in the first week of follicular phase (In patients with amenorrhea, at the time of referral to the clinic) in order to evaluate their endometrial thickness (ET) by transvaginal sonography and endometrial biopsy. The rest of the information was obtained by conducting interviews. The data were tested by χ2, t-test and logistic regression and statistical analysis was performed by using JMP software (Version 4; SAS Institute, USA). P-values less than 0.05 were considered significant. Results: Examination of endometrial biopsies (106) by one pathologist revealed that 46 (43.4%) cases had endometrial hyperplasias (EH), which were subsequently classified into 37 cases of simple and three cases of complex hyperplasias but six cases had cytological atypia. Meanwhile, 53 patients (50%) had proliferative and five (4.7%) had secretory endometria. Two cases, aged 28 and 38 years, were diagnosed as endometrial adenocarcinoma. The patients were divide into two groups with or without EH, except the two with adenocarcinoma. Mean age, BMI, and endometrial thickness were significantly higher in the hyperplasic group. Age >35 years (OR=3.62, p<0.01 ), bmi ≥30 (or="5.86," p<0.001) and endometrial thickness>7mm (OR=5.86, p<0.001 ) were identified as risk factors for endometrial hyperplasia. in multiple logistic regression analysis of age, bmi and et, age (p<0.0001) and et (p<0.01) were each an inde-pendent factor for the development of endometrial hyperplasia following adjustment for the other two variables. inter-menstrual spotting and menstrual irregularity were seen in 37 (80.43%) and 45 cases (97.83%) respectively. conclusion: the chances for eh in infertile women with pcos will increase by age, obesity and et thickness more than 7mm. however, age and et were recognized as independent risk factors for eh.< pan>

Keywords: Endometrial hyperplasia, Infertility, Endometrial biopsy, Transvaginal sonography, Amenorrhea, Polycystic ovary syndrome

To cite this article:


  1. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol. 1970;36:659-66.   [PubMed]
  2. Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J. 1997;38:11-5.   [PubMed]
  3. Marsden DE, Hacker NF. The classification, diagnosis and management of endometrial hyperplasia. Rev Gynecol Pract. 2003;3:89-97.
  4. Kurman RJ, Kaminski PF, Norris HJ. The behaviour of endometrial hyperplasia. A long-term study of untreted hyperplasia in 170 patients. Cancer. 1985;56:403-412.   [PubMed]
  5. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypi-cal endometrial hyperplasia: clinicopathologic analysis in cases with and without progesterone treatment. Int J Gynecol Cancer. 2004;14:348-53.   [PubMed]
  6. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum fertile.2000;3:101.   [PubMed]
  7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.   [P]
  8. Leon Speroff and Marc A. Fritz. Anovulation and the polycystic ovary. Clinical Gynecology Endocrinology and Infertility. 2005;7th ed. p: 465-98.
  9. Weber AM, Belinstone JL, Piedmonte MR. Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol. 1999; 93:594-8.   [PubMed]
  10. Cheung AP. Ultrasound and menstrual history in pre-dicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 2001;98:325-31.   [PubMed]
  11. Horn LC, Meinel A, Handzel R, Einenkel J. Histopa-thology of endometrial hyperplasia and endometrial carcinoma An update. Ann Diagn Pathol. 2007;11:297-311.   [PubMed]
  12. Fraquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endomet-rial hyperplasia in premenopausal women with abnor-mal menstrual bleeding. Am J Obstet Gynecol. 1999; 181:525-9.   [PubMed]
  13. Ricci E, Moroni S, Parazzini F, Surace M, Benzi G, Salerio B, Polverino G, Vecchia CL. Risk factors for endometrial hyperplasia: results from a case-control study. Int J Gynecol Cancer. 2002;12:257-60.   [PubMed]
  14. The Rotterdam ESHRE/ASRM-Sponsored PCOS con-sensus workshop group. Revised 2003 Consensus on diagnosis criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.   [PubMed]
  15. Tingthanatikul Y, Choktanasiri W, Rochanawutanon M, Weerakeit S. Prevalence and clinical predictors of endometrial hyperplasia in anovulatory women pre-senting with amenorrhea. Gynecol Endocrinol. 2006; 22:101-105.   [PubMed]
  16. Anastasiadis PG, Skaphida PG, Koutlaki NG, Gala-zios GC, Tsikouras PN, Liberis VA. Descriptive epide-miology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynecol Oncol. 2002; 21:131-4.   [PubMed]
  17. Novac L, Griogore T, Cernea N, Niculescu M, Cotar-cea S. Incidence of endometrial carcinoma in patients with endometrial hyperplasia. Eur J Gynecol Oncol. 2005;26:561-3.   [PubMed]
  18. Thom MH, Studd JW. Oestrogens and endometrial hyperplasia. Br J Hosp Med. 1980;23(5):508-9, 511-3.   [PubMed]
  19. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ2nd, Alberts D, Curtine J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gyne-cologic Oncology Group study. Cancer. 2006;106:812-9.   [PubMed]
  20. R Roterdom ESHRE/ASRM-Sponsored PCOS con-sensus workshop group. Revised 2003 consensus on diagnosis criteria and long-term health risks related to polycystic ovary sendrome. Fertile Steril. 2004;81:19-25.   [PubMed]


Home | About Us | Current Issue | Past Issues | Submit a Manuscript | Instructions for Authors | Subscribe | Search | Contact Us

"Journal of Reproduction & Infertility" is owned, published, and managed by Avicenna Research Institute .
Creative Commons License

This work is licensed under a Creative Commons Attribution –NonCommercial 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Journal of Reproductoin and Infertility (JRI) is a member of COMMITTEE ON PUBLICATION ETHICS . Verify here .

©2024 - eISSN : 2251-676X, ISSN : 2228-5482, For any comments and questions please contact us.